Skip to content
DataLookout
Menu

NCT06972056

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 36 → 39 locations
  2. Minor Study sites: 36 to 37
  3. Notable Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site contacts updated at 5 of 36 sites
  4. Minor Study sites: 35 to 36v14
  5. Minor Site contacts updated at 3 of 35 sitesv13
  6. Minor Study sites revised (35)v12
  7. Minor Trial sites expanded: 23 → 35 locationsv11
  8. Minor Trial sites expanded: 18 → 23 locationsv10
  9. Minor Study sites: 17 to 18v9
  10. Minor Study sites: 9 to 17v8
  11. Minor Study sites: 7 to 9v7
  12. Minor Start date changed from estimate of Jul 2025 to Jul 9, 2025
    • Site details revised at 1 of 7 sites
    v6
  13. Minor Study sites revised (7)v5
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 5 to 7
    v4
  15. Minor Site contacts updated at 1 of 5 sitesv3
  16. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)
Timeframe: Weeks 9-12 post-randomization compared to the 4 weeks prior to randomization

Secondary (4)

Migraine Specific Quality-of-Life - Role Function-Restrictive
Treatment Responder (propranolol vs. topiramate)
Headache Impact Test-6 (HIT-6)
Medication-Related Adverse Events

Arms and interventions

AtogepantActive comparator

Participants who are randomized to this arm will take up to 60mg daily for 12 weeks.

PropranololActive comparator

Participants randomized to this arm will take up to 160 mg daily for 12 weeks.

TopiramateActive comparator

Participants randomized to this arm will take up to 100 mg daily for 12 weeks .

Drugs: Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg

Sites

39 sites in 1 country